Published in Clin Chem on October 06, 2011
Serum free light chains should be the target of response evaluation in light chain multiple myeloma rather than urines. Blood (2016) 1.39
Improved monitoring of differences in serial laboratory results. Clin Chem (2011) 0.76
Serum protein electrophoresis in the evaluation of lytic bone lesions. Iowa Orthop J (2013) 0.75
Serum free light chain assays not total light chain assays are the standard of care to assess Monoclonal Gammopathies. Rev Bras Hematol Hemoter (2016) 0.75
Defining the impact of individual sample variability on routine immunoassay of serum free light chains (sFLC) in multiple myeloma. Clin Exp Immunol (2013) 0.75
Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients. Croat Med J (2015) 0.75
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol (2005) 5.64
Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem (2002) 4.24
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol (2003) 2.74
Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol (2008) 2.08
Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol (2006) 2.06
What is a significant difference between sequential laboratory results? J Clin Pathol (2007) 1.61
Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant (2005) 1.55
Appraisal of immunoglobulin free light chain as a marker of response. Blood (2008) 1.38
Outcome in renal Al amyloidosis after chemotherapy. J Clin Oncol (2011) 1.21
Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol (2007) 1.20
Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol (2011) 1.17
Quantitation of serum monoclonal proteins: relationship between agarose gel electrophoresis and immunonephelometry. Clin Chem (2009) 0.97
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
Multiple myeloma. N Engl J Med (2004) 10.81
Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc (2003) 9.96
A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med (2002) 8.63
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med (2007) 8.41
Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med (2006) 7.24
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell (2007) 7.24
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology (2007) 6.68
Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med (2008) 6.67
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med (2007) 6.07
Multiple myeloma. Blood (2008) 5.88
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood (2005) 5.82
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood (2009) 5.69
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med (2014) 5.08
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet (2010) 4.75
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood (2003) 4.67
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood (2005) 4.48
Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 4.39
POEMS syndrome: definitions and long-term outcome. Blood (2002) 4.35
Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem (2002) 4.24
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology (2007) 3.85
Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum (2010) 3.84
Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology (2009) 3.73
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol (2004) 3.43
Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol (2009) 3.42
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol (2012) 3.35
Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood (2002) 3.34
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol (2006) 3.20
Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology (2007) 3.08
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging (2010) 3.03
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med (2014) 2.99
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood (2004) 2.97
Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc (2007) 2.91
Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology (2003) 2.89
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc (2006) 2.88
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood (2007) 2.87
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clin Gastroenterol Hepatol (2011) 2.74
Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood (2003) 2.68
Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem (2005) 2.64
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol (2002) 2.63
Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc (2004) 2.62
Multiple myeloma: diagnosis and treatment. Mayo Clin Proc (2005) 2.62
Serum aminotransferase activity and mortality risk in a United States community. Hepatology (2008) 2.61
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc (2007) 2.55